The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).
 
Feng Tan
No Relationships to Disclose
 
Zhijie Wang
No Relationships to Disclose
 
Gang Feng
No Relationships to Disclose
 
Daqiang Sun
No Relationships to Disclose
 
Haitao Ma
No Relationships to Disclose
 
Tao Jiang
No Relationships to Disclose
 
Sihua Wang
No Relationships to Disclose
 
Hongxu Liu
No Relationships to Disclose
 
Weidong Hu
No Relationships to Disclose
 
Wei Liu
No Relationships to Disclose
 
Yuming Zhu
No Relationships to Disclose
 
Hecheng Li
No Relationships to Disclose
 
Hao Peng
No Relationships to Disclose
 
Qingchen Wu
No Relationships to Disclose
 
Weiyu Shen
No Relationships to Disclose
 
Shun Xu
No Relationships to Disclose
 
Quanren Zhang
No Relationships to Disclose
 
Yongtao Han
No Relationships to Disclose
 
Jie Wang
No Relationships to Disclose
 
Shugeng Gao
No Relationships to Disclose